HK1259348A1 - 雜環受限三環磺酰胺作為抗癌試劑 - Google Patents
雜環受限三環磺酰胺作為抗癌試劑Info
- Publication number
- HK1259348A1 HK1259348A1 HK19101714.2A HK19101714A HK1259348A1 HK 1259348 A1 HK1259348 A1 HK 1259348A1 HK 19101714 A HK19101714 A HK 19101714A HK 1259348 A1 HK1259348 A1 HK 1259348A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cancer agents
- heterocyclic
- tricyclic sulfonamides
- sulfonamides
- constrained tricyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562216172P | 2015-09-09 | 2015-09-09 | |
PCT/US2016/050688 WO2017044569A1 (en) | 2015-09-09 | 2016-09-08 | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1259348A1 true HK1259348A1 (zh) | 2019-11-29 |
Family
ID=56936551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK19101714.2A HK1259348A1 (zh) | 2015-09-09 | 2019-01-31 | 雜環受限三環磺酰胺作為抗癌試劑 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10759790B2 (zh) |
EP (1) | EP3347355B1 (zh) |
JP (1) | JP6955485B2 (zh) |
CN (1) | CN108349961B (zh) |
AR (1) | AR105975A1 (zh) |
CA (1) | CA2997784A1 (zh) |
HK (1) | HK1259348A1 (zh) |
TW (1) | TW201808930A (zh) |
WO (1) | WO2017044569A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017512766A (ja) | 2014-03-11 | 2017-05-25 | アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai | 抗癌剤としてのトリシクリル−2−アミノシクロアルカノール由来スルホンアミド |
JP2017507962A (ja) | 2014-03-11 | 2017-03-23 | アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai | 限定された三環式スルホンアミド |
WO2017024229A1 (en) * | 2015-08-06 | 2017-02-09 | Icahn School Of Medecine At Mount Sinai | Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols |
JP6966425B2 (ja) | 2015-09-09 | 2021-11-17 | アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai | 抗がん剤としての複素環式の限定された三環系スルホンアミド |
WO2021150697A1 (en) * | 2020-01-22 | 2021-07-29 | Icahn School Of Medicine At Mount Sinai | N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents |
WO2021150700A1 (en) * | 2020-01-22 | 2021-07-29 | Icahn School Of Medicine At Mount Sinai | N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents |
CN112778257A (zh) * | 2021-01-21 | 2021-05-11 | 香港科技大学 | 一种将糠醇氧化为二氢吡喃酮类衍生物的绿色方法 |
AU2022216880A1 (en) * | 2021-02-08 | 2023-08-10 | Rappta Therapeutics Oy | Substituted cyclic modulators of protein phosphatase 2a (pp2a) and methods using same |
WO2023245297A1 (en) * | 2022-06-23 | 2023-12-28 | University Of Ottawa | Ferroptosis inhibitors and uses thereof |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634766A (en) | 1983-10-31 | 1987-01-06 | Merck Frosst Canada, Inc. | 1,4-diaza-phenothiazines |
GB8510680D0 (en) | 1985-04-26 | 1985-06-05 | Smith Kline French Lab | Pyridine derivatives |
US4882351A (en) | 1987-10-14 | 1989-11-21 | Roussel Uclaf | Tricyclic compounds |
WO1995003279A1 (fr) | 1993-07-26 | 1995-02-02 | Eisai Co., Ltd. | Derives de sulfamide et d'ester sulfonique presentant chacun un heterocycle tricyclique |
WO1997030038A1 (fr) | 1996-02-15 | 1997-08-21 | Mitsubishi Chemical Corporation | Derives du diarylsultame |
US6333322B1 (en) | 1996-03-13 | 2001-12-25 | Eisai Co., Ltd. | Nitrogen-containing tricyclic compounds and drugs containing the same |
WO1999043683A1 (fr) | 1998-02-27 | 1999-09-02 | Eisai Co., Ltd. | Derives de benzothiazine condense heterocyclique |
MXPA03002445A (es) | 2000-09-20 | 2003-06-19 | Schering Corp | Imidazoles sustituidos como agonistas o antagonistas duales h1 y h3 de histamina. |
WO2003066040A1 (fr) | 2002-02-05 | 2003-08-14 | Ajinomoto Co.,Inc. | Compositions medicinales contenant une gabapentine ou une pregabaline et antagoniste a canal de calcium de type n |
TW200400816A (en) | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
CN101084209A (zh) | 2004-12-21 | 2007-12-05 | 德福根有限公司 | 具有Kv4离子通道活性的化合物 |
IT1362675B (it) | 2005-03-15 | 2009-06-25 | Menarini Internat Operations Luxembourg Sa | N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche |
EA200702208A1 (ru) | 2005-04-22 | 2008-04-28 | Алантос Фармасьютиклз Холдинг, Инк. | Ингибиторы дипептидилпептидазы-iv |
GB0508992D0 (en) | 2005-05-03 | 2005-06-08 | Novartis Ag | Organic compounds |
CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
WO2008121859A1 (en) | 2007-03-30 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions |
CN103748094B (zh) * | 2011-05-06 | 2016-06-29 | 扎夫根股份有限公司 | 三环磺酰胺化合物及其制备和使用方法 |
AU2012296528B2 (en) | 2011-08-16 | 2017-07-06 | Icahn School Of Medicine At Mount Sinai | Tricyclic compounds as anticancer agents |
CA2882826A1 (en) | 2012-08-24 | 2014-02-27 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
CN102942562B (zh) | 2012-12-05 | 2014-10-01 | 天津市斯芬克司药物研发有限公司 | 一种苯并咪唑衍生物及其制备方法和应用 |
CN105073117A (zh) | 2013-02-19 | 2015-11-18 | 西奈山伊坎医学院 | 作为抗癌剂的三环杂环化合物 |
JP2017512766A (ja) * | 2014-03-11 | 2017-05-25 | アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai | 抗癌剤としてのトリシクリル−2−アミノシクロアルカノール由来スルホンアミド |
JP2017507962A (ja) | 2014-03-11 | 2017-03-23 | アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai | 限定された三環式スルホンアミド |
WO2017024229A1 (en) | 2015-08-06 | 2017-02-09 | Icahn School Of Medecine At Mount Sinai | Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols |
JP6966425B2 (ja) | 2015-09-09 | 2021-11-17 | アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai | 抗がん剤としての複素環式の限定された三環系スルホンアミド |
WO2017044575A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents |
WO2017044571A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Tricyclic sultam sulfonamides as anticancer and neuroprotective agents |
WO2017044572A1 (en) | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Ring constrained diarylamino sulfonamides as anti-cancer agents |
-
2016
- 2016-09-08 CA CA2997784A patent/CA2997784A1/en not_active Abandoned
- 2016-09-08 US US15/758,045 patent/US10759790B2/en active Active
- 2016-09-08 JP JP2018512955A patent/JP6955485B2/ja active Active
- 2016-09-08 CN CN201680065550.9A patent/CN108349961B/zh not_active Expired - Fee Related
- 2016-09-08 WO PCT/US2016/050688 patent/WO2017044569A1/en active Application Filing
- 2016-09-08 EP EP16766454.9A patent/EP3347355B1/en active Active
- 2016-09-09 TW TW105129416A patent/TW201808930A/zh unknown
- 2016-09-09 AR ARP160102755A patent/AR105975A1/es unknown
-
2019
- 2019-01-31 HK HK19101714.2A patent/HK1259348A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2017044569A1 (en) | 2017-03-16 |
CN108349961B (zh) | 2022-02-18 |
TW201808930A (zh) | 2018-03-16 |
JP6955485B2 (ja) | 2021-10-27 |
AR105975A1 (es) | 2017-11-29 |
CA2997784A1 (en) | 2017-03-16 |
EP3347355A1 (en) | 2018-07-18 |
CN108349961A (zh) | 2018-07-31 |
US20180251456A1 (en) | 2018-09-06 |
JP2018526419A (ja) | 2018-09-13 |
US10759790B2 (en) | 2020-09-01 |
EP3347355B1 (en) | 2022-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1250959A1 (zh) | 硝基苄基衍生物抗癌試劑 | |
HK1259348A1 (zh) | 雜環受限三環磺酰胺作為抗癌試劑 | |
MA41107A (fr) | Compositions anti-cancéreuses | |
DK3243813T3 (da) | Tricyklisk spiro-forbindelse | |
IL254424A0 (en) | Disubstituted heterocyclic tricyclic compounds | |
HK1251465A1 (zh) | 包含三環雜環化合物的組合物 | |
ZA201900609B (en) | Sulfonamides as gpr40- and gpr120-agonists | |
IL283559A (en) | New heterocyclic anti-estrogens | |
IL253276A0 (en) | Anticancer compounds | |
EP3481806C0 (en) | 4-ANILINO-QUINOLINE COMPOUNDS AS ANTI-CANCER AGENTS | |
IL249907A0 (en) | Tricyclic substances containing a triazole ring | |
EP3298005C0 (en) | ANTI-CANCER COMPOUNDS | |
HUE054569T2 (hu) | Olajvisszavezetõ struktúra | |
ZA202000996B (en) | Anti-cancer agent | |
TH1601003731A (th) | สารประกอบไทรไซคลิกเป็นสารต้านมะเร็ง |